ライフサイエンスコーパス: glutamate carboxypeptidase II

1 1 is a potent hydroxamate-based inhibitor of glutamate carboxypeptidase II.

2 by the NAALADL1 gene, is a close homolog of glutamate carboxypeptidase II, a metallopeptidase that h

3 Inhibitors of glutamate carboxypeptidase II, an enzyme that inactivate

4 dic dipeptidase (NAAG peptidase activity) or glutamate carboxypeptidase II, and may also act as a NAA

5 anisms, such as increased kynurenic acid and glutamate carboxypeptidase II expression, are especially

6 ptidase-like 2 (NAALADL2) is a member of the glutamate carboxypeptidase II family, best characterized

7 Glutamate carboxypeptidase II (GCP II) catalyzes the ext

8 The enzyme glutamate carboxypeptidase II (GCP II) has been cloned f

9 or proteins in schizophrenia and to quantify glutamate carboxypeptidase II (GCP II) in order to explo

10 Two representative glutamate carboxypeptidase II (GCP II) inhibitors, 2-(hy

11 The expression of glutamate carboxypeptidase II (GCP II) is reduced in sel

12 However, the catalytic enzyme glutamate carboxypeptidase II (GCP II) rapidly hydrolyze

13 ore and after NAAG hydrolysis with exogenous glutamate carboxypeptidase II (GCP II) using high-perfor

14 The NAAG hydrolyzing enzyme, glutamate carboxypeptidase II (GCP II), activity was nor

15 ed and tested for their abilities to inhibit glutamate carboxypeptidase II (GCP II).

16 e synthesized and evaluated as inhibitors of glutamate carboxypeptidase II (GCP II, EC 3.4.17.21).

17 mbers include transferrin receptor 2 (TfR2), glutamate carboxypeptidase II (GCP2 or PSMA), N-acetylat

18 Glutamate carboxypeptidase II (GCPII or prostate-specifi

19 Glutamate carboxypeptidase II (GCPII) encodes for intest

20 Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to

21 Glutamate carboxypeptidase II (GCPII) has emerged as a p

22 Urea-based, low molecular weight ligands of glutamate carboxypeptidase II (GCPII) have demonstrated

23 The neuropeptidase glutamate carboxypeptidase II (GCPII) hydrolyzes N-acety

24 A series of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors have be

25 delta-Thiolactones derived from thiol-based glutamate carboxypeptidase II (GCPII) inhibitors were ev

26 We then evaluated glutamate carboxypeptidase II (GCPII) inhibitors, known

27 Prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII) is a promising tar

28 Glutamate carboxypeptidase II (GCPII) is an exopeptidase

29 Inhibition of glutamate carboxypeptidase II (GCPII) is effective in pr

30 Human glutamate carboxypeptidase II (GCPII) is involved in neu

31 to NAA and glutamate by the catalytic enzyme glutamate carboxypeptidase II (GCPII) reducing presynapt

32 Because glutamate carboxypeptidase II (GCPII) regulates both fol

33 eting the active site as well as exosites of glutamate carboxypeptidase II (GCPII), a prostate cancer

34 Glutamate carboxypeptidase II (GCPII), coded by the gene

35 orters/receptor (FT/R) and folate hydrolase, glutamate carboxypeptidase II (GCPII), from the terminal

36 cific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a suitable tar

37 Glutamate carboxypeptidase II (GCPII), localized on the

38 involving potent and selective inhibitors of glutamate carboxypeptidase II (GCPII), which converts th

39 MTHFR), reduced folate carrier 1 (RFC1), and glutamate carboxypeptidase II (GCPII).

40 Glutamate carboxypeptidase II (GCPII, NAALADase, or NAAG

41 Glutamate carboxypeptidase II may modulate excitatory ne

42 ic acid (1, 2-PMPA) is a potent inhibitor of glutamate carboxypeptidase II which has demonstrated rob

43 ith a catalytic mechanism similar to that of glutamate carboxypeptidase II yet distinct substrate spe